Halozyme Therapeutics HALO Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.51B+8.0% | $1.4B+12.4% | $1.24B+5.4% | $1.18B+8.7% | $1.08B+6.8% | ||
| $259.61M+13.5% | $228.77M+19.1% | $192.06M+3.1% | $186.24M+3.8% | $179.49M+12.6% | ||
| $1.25B+6.9% | $1.17B+11.1% | $1.05B+5.9% | $992.43M+9.7% | $904.82M+5.7% | ||
| 82.8%-0.8pp | 83.6%-0.9pp | 84.5%+0.3pp | 84.2%+0.8pp | 83.4%-0.9pp | ||
| $92.25M+13.2% | $81.49M+16.4% | $70.03M-1.7% | $71.24M-4.7% | $74.74M-5.5% | ||
| $222.61M+7.5% | $207.09M+20.2% | $172.31M+2.9% | $167.47M+3.7% | $161.56M+4.7% | ||
| $996.47M+7.4% | $927.61M+83.5% | $505.45M+1.9% | $496M+1.9% | $486.84M+5.0% | ||
| —— | —— | $737.4M+8.0% | $682.67M+14.3% | $597.47M+8.3% | ||
| $19.11M+5.4% | $18.13M+2.1% | $17.76M-1.3% | $17.98M-0.7% | $18.11M+0.1% | ||
| $15.97M-25.6% | $21.47M-18.3% | $26.3M-4.2% | $27.44M+7.3% | $25.58M+7.7% | ||
| —— | —— | $745.94M+7.8% | $692.13M+14.4% | $604.93M+8.6% | ||
| $154.53M+3.0% | $149.99M-0.3% | $150.45M+11.6% | $134.85M+12.8% | $119.57M+5.8% | ||
| —— | —— | $595.49M+6.9% | $557.28M+14.8% | $485.36M+9.3% | ||
| —— | —— | $4.75+8.7% | $4.37+16.2% | $3.76+9.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Halozyme Therapeutics's revenue?
- Halozyme Therapeutics (HALO) generated $1.5B in revenue over the trailing twelve months, up 39.1% year over year.
- Is Halozyme Therapeutics profitable?
- Halozyme Therapeutics reported $608.5M in net income over the trailing twelve months, a 47.9% net margin.
- What are Halozyme Therapeutics's profit margins?
- Gross margin is 82.8% and operating margin is 59.3%, with a 47.9% net margin.
- What is Halozyme Therapeutics's earnings per share?
- Halozyme Therapeutics's diluted EPS over the trailing twelve months is $4.91.
- Where does Halozyme Therapeutics's income statement data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
